Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching

Abstract Background Traditional bortezomib, thalidomide, and dexamethasone (VTd) regimens for patients with newly diagnosed multiple myeloma (NDMM) include doses of thalidomide up to 200 mg/day (VTd‐label). Clinical practice has evolved to use a lower dose (100 mg/day) to reduce toxicity (VTd‐mod),...

Full description

Bibliographic Details
Main Authors: Philippe Moreau, Cyrille Hulin, Sonja Zweegman, Mahmoud Hashim, Yannan Hu, Bart Heeg, Carla deBoer, Veronique Vanquickelberghe, Tobias Kampfenkel, Jianming He, Annette Lam, Sarah Cote, Pieter Sonneveld
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:eJHaem
Subjects:
clinical trials
monoclonal antibodies
multiple myeloma
thalidomide
Online Access:https://doi.org/10.1002/jha2.129

Internet

https://doi.org/10.1002/jha2.129

Similar Items